F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Open Access
- 25 October 2016
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (45) , 12809-12814
Abstract
There is an important medical need for new antifungal agents with novel mechanisms of action to treat the increasing number of patients with life-threatening systemic fungal disease and to overcome the growing problem of resistance to current therapies. F901318, the leading representative of a novel class of drug, the orotomides, is an antifungal drug in clinical development that demonstrates excellent potency against a broad range of dimorphic and filamentous fungi. In vitro susceptibility testing of F901318 against more than 100 strains from the four main pathogenic Aspergillus spp. revealed minimal inhibitory concentrations of ≤0.06 µg/mL—greater potency than the leading antifungal classes. An investigation into the mechanism of action of F901318 found that it acts via inhibition of the pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase (DHODH) in a fungal-specific manner. Homology modeling of Aspergillus fumigatus DHODH has identified a predicted binding mode of the inhibitor and important interacting amino acid residues. In a murine pulmonary model of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to the azole class of antifungals and a strain displaying an azole-resistant phenotype. F901318 is currently in late Phase 1 clinical trials, offering hope that the antifungal armamentarium can be expanded to include a class of agent with a mechanism of action distinct from currently marketed antifungals.Keywords
This publication has 33 references indexed in Scilit:
- Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human HealthPLOS Pathogens, 2013
- Hidden Killers: Human Fungal InfectionsScience Translational Medicine, 2012
- Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosisBulletin of the World Health Organization, 2011
- Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitisClinical Microbiology and Infection, 2010
- Therapy for fungal diseases: opportunities and prioritiesTrends in Microbiology, 2010
- Phylogeny.fr: robust phylogenetic analysis for the non-specialistNucleic Acids Research, 2008
- Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicansThe FEBS Journal, 2006
- Strains and Strategies for Large-Scale Gene Deletion Studies of the Diploid Human Fungal Pathogen Candida albicansEukaryotic Cell, 2005
- Ectopic Expression of URA3 Can Influence the Virulence Phenotypes and Proteome of Candida albicans but Can Be Overcome by Targeted Reintegration of URA3 at the RPS10 LocusEukaryotic Cell, 2004
- Extra Copies of the Aspergillus fumigatus Squalene Epoxidase Gene Confer Resistance to Terbinafine: Genetic Approach to Studying Gene Dose-Dependent Resistance to Antifungals in A. fumigatusAntimicrobial Agents and Chemotherapy, 2004